Title

Presentation

Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.22, expectations were $2.13.

Operator: Thank you for standing by. Welcome to the Merck & Co., Inc., Rahway, New Jersey U.S.A. Quarter 1 Sales and Earnings Conference Call. This call is being recorded. If you have any objections, you may disconnect at this time. I would like to turn the call to Mr. Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin.

Peter Dannenbaum: Thank you, Dustin, and good morning, everyone. Welcome to the First Quarter 2025 Conference Call for Merck & Co., Inc., Rahway, New Jersey U.S.A. Speaking on today’s call will be Rob Davis, Chairman and Chief Executive Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Li, President of Research Labs. Before we get started, I’d like to point out that we have items in our GAAP results such as acquisition-related charges, restructuring costs, and certain other items that we have excluded from our non-GAAP results. There is a reconciliation in our press release. I will also remind you that some of the statements that we make today may be considered forward-looking statements within the meaning of the safe harbor provision of The U.S. Private Securities Litigation Reform Act of 1995.

Such statements are made based on the current beliefs of our company’s management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Our SEC filings, including Item 1A, and the 2024 10-Ks identify certain risk factors and cautionary statements that could cause the company’s actual results to differ materially from those projected in any of our forward-looking statements made this morning. Merck & Co., Inc., Rahway, New Jersey, USA, undertakes no obligation to publicly update any forward-looking statements. During today’s call, a slide presentation will accompany our speakers’ prepared remarks.

These slides, along with the earnings release, today’s prepared remarks, and our SEC filings are all posted to the Investor Relations section of our company’s website. With that, I’d like to turn the call over to Rob.

Rob Davis: Thank you, Peter. Good morning, and thank you for joining today’s call. Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline. We are working with focus and urgency to both realize the full potential of our near-term opportunities and to rapidly progress the next wave of innovation that will positively impact the lives of the patients we serve and drive future value creation for all of our stakeholders. In what is a dynamic global environment, we continue to work with regulators and policymakers around the world to tackle some of the biggest health challenges and ensure patient and customer access to our life-saving and life-improving medicines and vaccines.

Over the last few years, we’ve been evolving our supply chain strategy in an effort to better balance our manufacturing footprint, which aligns well with the new administration’s efforts to regrow the US manufacturing base. This can be seen by our efforts beginning with the passing of the Tax Cut and Jobs Act and accelerated since the pandemic. Of note, since 2018, we’ve invested $12 billion in US manufacturing and we’ve committed to an additional $9 billion plus for projects through 2028. Our investments are leading to more of our products for US patients being manufactured in the US as well as more opportunities for export. Turning to our first quarter results, our performance was in line with our expectations with revenue of $15.5 billion reflecting strength in oncology, animal health, and increasingly meaningful contributions from the continued strong launches of WINREAVER and Cafaxib.

As we look forward, we remain confident in our outlook for improved growth in the second half of the year. Considering the current environment, we are maintaining our full-year revenue and EPS guidance excluding business development charges which Caroline will speak to in more detail. The benefit from improved foreign exchange is offset in part by approximately $200 million of expected cost from tariffs implemented to date primarily between the US and China and to a lesser degree Canada and Mexico. With respect to potential additional tariffs by the US, specifically on pharmaceuticals, our global supply chain and current inventory levels put us in a good position to navigate potential near-term impacts. And our ongoing efforts to locate more manufacturing in the US for US supply, including for the majority of our upcoming new products, will help us manage over the medium and long term.

As I look at how we’ve started 2025, I’m proud of the continued advancement of our research efforts. Recently, we presented important phase three data for wind repair in additional patient populations supporting the strong potential for this product to improve the lives of more people living with pulmonary arterial hypertension. In addition, our HIV pipeline is now coming into sharper focus, with data presentations from two phase three trials of the zolotrovir-based regimens. And new clinical trial starts and regulatory submissions in oncology reinforce our belief that we are well-positioned for long-term leadership with the promise of helping even more patients with cancer. The success of biopharmaceutical innovation on the scale we’re driving is not measured in quarters, but rather in years.

And we’re seeing compelling progress on this front. Since 2021, we’ve nearly tripled our late-phase pipeline through both the advancement of internally discovered compounds as well as the completion of numerous important business development transactions across multiple therapeutic areas of great unmet need including oncology, cardiometabolic, ophthalmology, and immunology. Together, our efforts have resulted in an expanded late-phase pipeline comprising programs having potential commercial opportunity of over $50 billion by the mid-2030s. Wind rebar and CapVaxin represent the initial launches from this robust pipeline of 20 promising potential new growth drivers we expect to come to the market over the next few years almost all of which have blockbuster potential.

Looking ahead, we have a rich slate of data readouts presentations, filings, and additional approvals. Our pipeline includes some of the world’s most scientifically advanced modalities and Dean and our research colleagues are advancing several molecules that have foundational multi-indication potential in areas of significant unmet need. We’ve also deepened and extended our commitment to early research and development. And over the next few years, expect many of these programs to advance to Phase two and to become visible to you. Thanks to the incredible efforts of our dedicated team and the strong progress we are achieving, we believe that we’re well-positioned to successfully navigate through the KEYTRUDA LOE period. And our work is not finished.

Science and value-driven business development remains a top priority. And we continue to assess opportunities with urgency, and an eye toward driving near and long-term growth and value creation. In summary, our results reflect the continued demand for breakthrough therapies and novel solutions that can address global health challenges. We’re leveraging our scientific leadership to deliver the next wave of innovation that can save and improve lives around the world. Our commercial performance today continues to enable the advancement of our pipeline and in turn create long-term value for patients, customers, and shareholders. We remain confident in our strategic direction, our commitment to research and development as the source for sustainable value creation, and our enduring promise to positively impact patients.

With that, I’ll turn the call over to Caroline.

Caroline Litchfield: Thank you, Rob. Good morning. As Rob noted, first-quarter performance was in line with our expectations. The fundamentals of our business remain healthy, fueled by robust global demand for our innovative portfolio. We are confident in our ability to deliver on the promise of today while we make strategic investments to enable the innovations of tomorrow leveraging leading-edge science to save and improve lives around the world. Now turning to our first-quarter results, total company revenues were $15.5 billion, a decrease of 2%. Or an increase of 1% excluding the impact of foreign exchange. As expected, results were impacted by a decline in sales of Gardasil in China, of approximately $1.1 billion reducing growth excluding foreign exchange by seven percentage points.

Excluding these sales and the impact from foreign exchange, global growth was 8% primarily driven by new products, WinRevair and Capfaxiv, as well as strength in oncology and animal health. The following revenue comments will be on an ex-exchange basis. In oncology, sales of Keytruda grew 6%, to $7.2 billion. Global growth was driven by increased uptake from earlier-stage cancers, and robust demand for metastatic indications. In the earlier stage setting, growth was driven by increased utilization in triple-negative breast cancer, renal cell carcinoma, and non-small cell lung cancer. In metastatic disease, we saw increased use of KEYTRUDA in combination with PADCEF in first-line locally advanced urothelial cancer. As well as Keytruda in combination with chemotherapy in first-line endometrial cancer.

In the US, as previously communicated, growth was negatively impacted by approximately $250 million due to the timing of wholesaler purchases. Our broad oncology portfolio achieved strong growth driven by Wellyreg with sales increasing 63% to $137 million due to increased use in certain patients with previously treated advanced renal cell carcinoma in the US. Welireg is now the market leader in the treatment of patients with advanced renal cell carcinoma following prior therapies. In vaccines, GARDASIL sales were $1.3 billion, a decrease of 40% driven by China where we see elevated channel inventories and continued soft demand. In the rest of the world, growth was 16%. In the US, sales benefited from price and demand. Outside the US and China, growth was driven by higher overall demand including from the catch-up cohort in Japan.

In pneumococcal, Cafaxib sales were $107 million driven primarily by demand from the retail pharmacy segment. We have made great progress in the early stages of this launch, and are well-positioned to help protect adults from invasive pneumococcal disease. Vaxnuvan sales increased 7% as growth from launches in international markets was partially offset by competitive pressures in the US. In cardiovascular, the strong momentum of the ongoing launch of WinRefer continues, with global sales of $280 million. The launch continues to perform in line with our high expectation and we remain excited about the significant benefit WinRevair is providing for patients. In the US, more than fourteen hundred new patients received prescriptions during the quarter.

We are continuing to see a steady increase in the percentage of new prescriptions for patients whose background PAH therapies do not include apostacyclin. Outside the US, we continue to progress with launches and reimbursement. Overall, we are very pleased with the uptake of win Rever, and look forward to positively impacting the lives of more patients with pulmonary arterial hypertension. The strength of the additional data from the clinical development program which Dean will speak to in a moment, provides further confidence to physicians and patients. And supports our belief in WinRev’s significant potential. Our animal health business delivered another quarter of robust growth. With sales increasing 10%. Livestock growth reflects higher demand across all species, as well as the benefit from the timing of sales in ruminants, and sales from the Aqua portfolio acquired from Elanco.

Companion animal sales growth reflects price. I will now walk you through the remainder of our P&L and my comments will be on a non-GAAP basis. Gross margin was 82.2%, an increase of one percentage point driven by favorable product mix. Operating expenses decreased to $6.1 billion. There were no significant business development expenses in the quarter, compared with the $656 million charge a year ago. Excluding this charge, operating expenses grew 6% reflecting disciplined investments in support of our robust early and late-phase pipeline, and key growth drivers. Other expense was $75 million. Our tax rate of 14.2% benefited from certain discrete items. Taken together, earnings per share were $2.22. Now turning to our 2025 non-GAAP guidance.

As Rob noted, we are maintaining our full-year revenue guidance of between $64.1 and $65.6 billion. This range represents growth of 1% to 3% excluding a negative impact from foreign exchange of approximately 1% using mid-April rates. Our gross margin assumption is now approximately 82%. This includes approximately $200 million in costs related to the tariffs implemented to date. Operating expenses are now assumed to be between $25.6 and $26.6 billion. This range now includes a $200 million payment related to the license agreement with Hungry Pharma, which is expected to close in the second quarter. It also includes the $300 million tech transfer payment related to Lenovo which remains in our guidance but has not yet occurred. As a reminder, our guidance does not assume additional significant potential business development transactions.

Other expense is expected to be between $300 million and $400 million. We assume a full-year tax rate between 15.5% and 16.5%. We assume approximately 2.51 billion shares outstanding. Taken together, we expect EPS of $8.82 to $8.97. This range includes a negative impact from foreign exchange of more than 20¢ using mid-April rates. Recall, our prior guidance range was $8.88 to $9.03. If not for the one-time charge of $200 million related to Hongray, or per share our guidance range is unchanged. As you consider your models, there are a few items to keep in mind. Following the successful HPV catch-up vaccination program in Japan, we expect uptake to moderate as future sales will predominantly reflect the primary age cohort. As a result, global Gardasil growth excluding China while still strong, is anticipated to slow going forward.

For Keytruda, the timing of wholesaler purchasing in the US negatively impacted sales by approximately $250 million in the first quarter, and is expected to positively impact sales by roughly the same amount in the third quarter. As a reminder, we lowered the list prices for the Januvia family of products in the US at the beginning of 2025. The lower list prices reduced the rebate amount our company pays to Medicaid. As a result, we expect higher net sales for these products in 2025. First-quarter sales of the Januvia family of products in the US also benefited by more than $100 million from favorable one-time true-ups. Now turning to capital allocation. Where our strategy remains unchanged. We will continue to prioritize investments in our business to drive near and long-term growth and returns for our shareholders.

Our company is rapidly moving towards a future with a more diversified portfolio of growth drivers. As we continue to assess our business, we are likely to take actions that will seek to maximize the potential of these opportunities by investing with discipline while transforming our business to drive continuous productivity across the company. We intend to communicate more about these efforts later this year. We remain committed to our dividend with the goal of increasing it over time. Business development remains an important priority. We continue to actively evaluate opportunities to execute additional science-driven value-creating transactions. We increased our share repurchases in the quarter to approximately $1.2 billion similar to the full-year amount in 2024.

We expect the pace of repurchase to continue at this level given our strong balance sheet. Our top priority, however, remains to invest fully behind our growth drivers and pipeline, as well as business development. To conclude, we are confident in the outlook for our business driven by our strong portfolio and exceptional pipeline. With investment in innovation, and our ongoing focus on execution we are well-positioned to deliver value to patients, customers, and shareholders now and well into the future. With that, I’d now like to turn the call over to Dean.

Dr. Dean Li: Thank you, Caroline. Good morning. Progress continued in the first quarter with a steady cadence of positive clinical and regulatory milestones. Today, I will provide updates from programs in cardiometabolic disease, HIV, vaccines, and we’ll close with oncology. Starting with cardiometabolic disease, since its first approval just over a year ago, winrevir, the first and only active in signaling inhibitor for the treatment of pulmonary arterial hypertension, has continued to generate clear evidence of benefit for a broad spectrum of patients with PAH. Last month, detailed results from the phase three ZENITH trial evaluating high-risk patients with PAH, presented at the American College of Cardiology’s ACC 25 conference.

The findings showed an important 76% risk reduction in the composite of all-cause death lung transplantation, and PAH hospitalization with the Kaplan Meier curve illustrating an early and sustained separation as early as four to five weeks after initiating initiation of windrow bearer. Results were published simultaneously in the New England Journal of Medicine. Zenith is the first positive trial in PAH with a primary endpoint comprised entirely of major outcome measures and the first to be stopped early for overwhelming efficacy. The significant reduction in risk of major morbidity and mortality events reinforces WinRevir’s efficacy. The safety profile in Zenith was generally consistent with that observed in previous studies. As a reminder, prompted by the early stoppage of the zenith study, and a review of the totality of data from the winrevir clinical program to date, the external steering committee determined that the Phase III Hyperion study had lost clinical equipoise and should also be stopped early.

All participants have now been given the option to receive winravir. We anticipate sharing data from the Hyperion study later this year. The clinical benefit and statistically significant improvement observed across a range of patients receiving winravir in the STEALAR and ZENITH study provide strong evidence for its potential to be practice-changing and to alter the trajectory for patients with this devastating disease. The clinical program also includes the ongoing long-term extension study, Suteria, as well as the phase two light ray study, which is being conducted to support the development of an auto-injector option for patients. In addition, the phase two CADANCE study exploring the potential in pulmonary hypertension due to left heart disease a specific segment within WHO group two, has completed recruitment and is on track for completion later this year.

We continue to bolster our portfolio of candidates targeting cardiometabolic disease. In March, we announced an exclusive license agreement with Hungry Pharma, for HRS five three four six an investigational oral small molecule lipoprotein a or LP little a formation inhibitor. Elevated levels of LP little a in the blood are an inherited atherosclerotic cardiovascular disease risk factor for which there are currently no approved treatment options. Hong Rui recently initiated a phase two clinical trial for HRS five three four six in China. We are planning a robust global clinical development program that expands and complements our broader cardiometabolic pipeline. Next to vaccines. We continue to secure regulatory approvals globally for Cavaxib.

More recently, the European Commission granted approvals for active immunization for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in adults. This is based on safety and immunogenicity data from multiple pivotal studies in the program and is the fourth approval for building on prior approvals in The US, Canada, and Australia. GARDASIL nine was recently approved by the National Medical Products Administration of China to help prevent certain related cancers and diseases in males 16 to 26 years old, making it the first nine-valent HPV vaccine approved for certain males and females in China. Turning to HIV. Detailed results from two pivotal phase three trials evaluating adults with virologically suppressed HIV-one who switched to the investigational once-daily oral fixed-dose combination of doravirine and ezlotrovir an investigational nucleoside reverse transcriptase translocation inhibitor were presented at the conference on retrovirus and opportunistic infections in March.

In both trials, at week forty-eight, doravirine and islacivir met the primary efficacy success criteria for non-inferiority to comparator antiretroviral therapies and primary safety objectives. The combinations of doravirine and enzlotrovir is the first complete two-drug regimen without an integrase strand transfer inhibitor to demonstrate comparable efficacy and safety to the three-drug insti-based regimen Biktarvy. In a phase three trial. We plan to submit applications for marketing authorization to regulatory agencies by midyear. These data and additional programs evaluating longer-acting regimens for treatment and pre-exposure prophylaxis underscore our ongoing commitment to finding new options that address the evolving needs of people at risk of and living with HIV.

Moving to oncology. Last month, at the European Lung Cancer Congress, we announced detailed findings from a pivotal Phase III trial evaluating a six-week dosing regimen of the investigational subcutaneous fixed-dose combination of pembrolizumab and ver hyaluronidase alpha. With chemotherapy versus intravenous Keytruda with chemotherapy. The study met its dual primary endpoints demonstrating non-inferior pharmacokinetics for subcutaneous pembrolizumab versus intravenous Keytruda. Consistent results were also reported for efficacy and safety endpoints across treatment arms. The median time for administration of subcutaneous pembrolizumab given every six weeks was approximately two minutes. A meaningful reduction compared to the time needed to administer Keytruda as an IV infusion.

Of note, at the American Association Cancer Research meeting next week, data from another study evaluating a three-week dosing regimen will be presented. The FDA has set up PDUFA date of September 23 and the European Medicines Agency is reviewing the application. We are seeking approval for both a six-week and a three-week dosing option. If approved, subcutaneous pembrolizumab would provide an important option for health care systems and patients, most notably for those in earlier stage settings Keytruda continues to have an unparalleled breadth of approvals and a significant impact for patients. The FDA granted priority review for Keytruda as part of a perioperative treatment regimen for patients newly diagnosed with stage III or IVA resectable locally advanced head and neck squamous cell carcinoma based on the keynote six eighty-nine study.

The PDUFA date is June 23. As a reminder, this is the first trial in twenty years for patients with resected locally advanced head and neck squamous cell carcinoma and the first phase three trial to show a statistically significant event-free survival benefit of neoadjuvant plus adjuvant therapy for newly diagnosed patients in this setting. Earlier intervention has the potential to improve outcomes, and reduce the burden of disease in this patient population. Results will be submitted to regulatory agencies and, if approved, this will mark the tenth indication of a KEYTRUDA-based regimen for the treatment of an earlier stage cancer. Detailed findings will be presented at the American Association for Cancer Research meeting next week where it may be important to scrutinize the Kaplan Meier plot the divergence of the curves as a sign of event-free survival benefit.

Based on the LightSPARK four and LightSPARK five trials, we received the first conditional European Commission approval for Wellerig. For the treatment of adults with von Hippel Lindau disease who require therapy for associated localized renal cell carcinoma central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors. And advanced clear cell RCC that progressed following two or more lines of therapy that included a PD-one or a PD L1 inhibitor at least two vascular endothelial growth factor targeted therapies. Please mark your calendars for the evening of Monday, June 2, for an investor event at the 2025 ASCO Annual Meeting in Chicago where we will provide an update on pipeline progress and the latest on our oncology strategy.

Finally, we have a number of near-term milestones to look out for this year, including in oncology upcoming PDUFA dates for keynote six eighty-nine and earlier stage head and neck squamous cell carcinoma in June, subcutaneous pembrolizumab in September, In RSV, the upcoming PDUFA for clozroblimab in June in the cardiometabolic space anticipated results from three phase three registration enabling studies evaluating our oral PCSK9 inhibitor candidate, enlicitide. For the treatment of hypercholesterolemia, and the scheduled fall primary completion date of the phase two CADANCE study evaluating winravir in pulmonary hypertension due to left heart disease as well as the final readout from the phase three HYPERIAN study. Lastly, in HIV, filing for doravirin and enzotrovir regimen and results from the Phase IIa trial for MK-eight thousand five hundred twenty-seven a novel NRTTI candidate as a potentially important once-monthly oral option for pre-exposure prophylaxis.

In closing, we continue to advance our pipeline and execute on our strategy with speed and rigor, I look forward to providing further updates on our progress. And now I turn the call back to Peter.

Peter Dannenbaum: Thanks, Dean. Dustin, we’re ready for Q and A. We request that analysts limit themselves to one question, please. Ladies and gentlemen, you wish to ask a question, please press 1 on your telephone keypad. You may withdraw your question at any time by pressing 2. If you’re using a speakerphone, please pick up the handset before pressing the numbers. Once again, if you have a question, you may press 1. One moment, please, for our first question. Our first question is from Geoff Meacham from Citibank. Go ahead. Your line is open.

Geoff Meacham: I guess I’ll kick it off with a tariff question. So Rob, I recognize it’s hard to talk specifics. But maybe at a high level, can you talk about Merck’s mitigating strategies as an offset whether it’s a new CapEx cycle, whether it’s changing the elements of the supply chain or even raising US price? Thanks so much.

Rob Davis: Yeah. No. Geoff, I appreciate the question. And, you know, obviously, Caroline spoke to the tariffs we’ve included. In our earnings so far, $200 million. And just to be clear, relates to the existing tariffs that have been announced largely between China and the US and to a lesser extent, Canada and Mexico. I think you’re really referring to the potential for further sector-specific tariffs that could come and what we’re doing. And in that regard, you know, we’ve been very focused, and I tried to highlight this in the script. We’ve actually had started to change and rebalance our supply chain strategy going back actually beginning with the Tax Cut and Jobs Act. Where we started moving more towards being able to have US for US Europe for Europe, and Asia for Asia.

And we’ve been in the process of doing that. That was a big part of where we announced that we’ve spent $12 billion since that time to date. And then we expect to spend an additional 9 plus billion dollars I expect, frankly, that number is gonna grow. Going forward. So we have already been in the process of changing our supply chain. But what we’ve done is specifically in the near term, we have, I think, done a good job of managing our M. So as you look at 2025, we’re well-positioned with inventory to be able to mitigate anything we could see in the short term. And then in the medium to long term, we’ve already started to identify where we can either reposition our own manufacturing, so, change the priorities of existing plants, bring on external manufacturing, in some cases, to bridge gaps.

And then finally, to build internal manufacturing long term. So that we have that in our base going forward. So, really, as I look at it, short term, I think we’re in a good shape. Medium and long term, we’re taking the steps to position ourselves. And that really is our main efforts. We are not using and do not really see price at the lever. For tariffs. Just given there’s always limitations in what you can do there. So for us, it’s more about how do we optimize our supply chain. But, again, a lot of what we’re doing now, frankly, we were already underway in. So in many ways, we are aligned with what the administration is wanting to do and feel that we are in a position to be able to do that quite effectively. Great. Thanks, Geoff. Next question, please, Dustin.

Tim Anderson: Our next question is from Tim Anderson from Bank of America. So I want to ask about long-term guidance, Rob. It was something I asked last quarter. I wanted to ask again. So lots of concerns about KEYTRUDA going into IRA, facing patent expiry at the end of twenty-eight. And in my view, unless you guys kinda give clarity on what that means, downstream at ’28. My fear is gonna continue to haunt the stock and now trades at single-digit p multiple, which is a level that Merck shares have not been other than once in the last twenty-five years, you know, an o nine after you buy sharing plow. So last quarter, when I asked that, you seem to imply you might give it at some point. I’m wondering where you are on that line of thinking as the stock continues to kind of drift lower. Thank you.

Rob Davis: Yeah. So Tim, thanks for the question. What we tried to do at the JPMorgan conference and I think everyone is aware is really highlight the confidence we have in our long term by focusing on the strength of the pipeline. I commented in our script that we have over 20 new products that we see coming over the next few years. Almost all of which have blockbuster potential. And if you look at the totality of those, as you look forward, this really makes up the bulk of what is the $50 billion plus potential we see out in the early to mid-twenty thirties. So you know, I think that gives people a sense of what we’re doing, whether we go beyond that to give specific line by line guidance. As of right now, we do not have a plan to do that, but we are continuing to evaluate it.

And we’ll, you know, take a sense of where the majority of investors have a view on that. Many people, frankly, disagree with you that we’ve heard from. Right. Tim. Next question, please, Dustin.

Luisa Hector: Next question is from Luisa Hector from Berenberg. Go ahead. Your line is open.

Luisa Hector: Hello. Thanks for taking my question. Perhaps you could comment on some of the changes we’re seeing within the FDA and the HHS particularly, with reference to vaccines and the outlook there. Thank you.

Dr. Dean Li: Yeah. This is Dean. Thanks for the question. In specific relationship to the FDA, I would just say we’ve listed programs with imminent PDUFA dates, like clasorbimab, subcu, Keynote six eighty-nine, And all of our communications have suggested that they’re all on track. There’s actually very active dialogue with FDM programs with near-term filings, including enlista and also, for example, when we’re bearer as we speak about potential label changes. What we can’t comment is the mid to long-term sort of impact of the many FDA personnel transitions. And we’ll just have to see and be very watchful for that. But in the imminent PDUFA date and in the active dialogues that we’ve had on programs that we’ve been talking to them for the last year year and a half, we haven’t seen any shift in timelines.

Peter Dannenbaum: Great. Thanks, Luisa. Next question, please, Dustin.

Vamil Divan: Next question is from Vamil Divan from Guggenheim Securities. Go ahead. Your line is open.

Vamil Divan: Maybe, again, just more macros or big picture questions here. I have two, like, clearly. So one, you mentioned business development is a top priority. I’m wondering if you could just sort of comment on the sort of environment for business development now given all the macro volatility and the unknowns on tariffs? Etcetera. Just you know, mercy. Willing to do a you know, you know, larger sort of deal or maybe a more meaningful sized bolt-on deal. And also from the sort of seller side, is there, you know, willingness to sell at this time? So any insight there would be appreciated. The second topic that comes up a lot now is for the potential for international reference pricing of some sort. Where US prices may get tied in some way to ex-US prices. Obviously, a lot of unknowns there too, but just if you can comment on your perspective on that or any insights you might have on that potentially becoming a reality. Thank you.

Rob Davis: Yeah. No. Thanks, Vamil, for the questions. On the first question, the macro environment and what does it mean from a business development perspective, maybe just to provide context to be clear, our focus on business development is unchanged. Our desire and belief that we need to continue to identify new science-based opportunities to continue to build on the pipeline. Is unchanged, and so our strategy continues. As we look at the environment, I mean, it clearly the what’s happening does make it more complex. To get things done because the uncertainty everyone is wrestling with. And we are doing everything we can to make sure we reflect that as we think about value and what we are willing to pay in that environment.

But it’s not stopping us from being aggressive and wanting to move forward and do deals. As it relates to the sellers, I would say that, you know, we continue to see at least in the conversations we’ve had, a little bit of a disconnect between what is the reality of the market that the sellers face and what is the expectation for value that they have. I don’t think they have fully yet aligned to the realities where we are today. And so we continue to move forward, but that is kind of the environment we seek. And but I am confident that you are gonna see us get some stuff done as we move forward because we got things in the queue that we’re looking for. And then as it relates to the most favored nations question, I don’t wanna speculate on what the administration might do specifically, but I would say, generally, you know, we recognize, I recognize, and I think the industry recognizes that price differential that exists between The United States and the rest of the world on for our innovative medicines needs to be addressed.

We are open and willing to work with the administration to do that. And I think it’s important that I would highlight a few areas that we see as the focal areas. First and foremost, we as an industry and Merck continue to believe PBM reform would be one important step. If you look at the fact that over 50¢ of every dollar goes somewhere in the middle, so the man the discoverers and manufacturers only get less than half of every dollar. If we could find a way to bring more of that back to the patient at the pharmacy counter, that could meaningfully reduce prices in The US. That would be an important step to do to lessen the differential. And then secondly, and I agree with there was I think you probably saw the recent commentary from some of my peers but I agree with the fact that we have to continue to encourage foreign governments to understand that they need to give fair value for the innovation we bring.

And that they give access to their patients, so that we can bring the medicines to them. And it’s at prices that reward us for the risk and innovation that we have. And I think that that’s also an important element. We are spending time individually as a company and along with our other industry peers promoting that point everywhere we can around the world. And we will continue to do that. And then as I mentioned, lastly, we’re very open to working with the administration to find solutions to address this. But the important thing is we need to make sure we protect access in The United States and we protect the innovation engine we have and the jobs it creates, and the strength of this industry as an important contributor to The United States.

We don’t want to lose the leadership we have in this important field and that’s what we’re trying to advocate for as we work with the administration.

Peter Dannenbaum: Thank you, Vamil. Next question, please.

Chris Schott: Next question is from Chris Schott from JPMorgan. Go ahead. Your line is open.

Chris Schott: Great. Thanks so much. Just had one question, just a quick follow-up on an earlier one. On the question, can you just talk about GARDASIL and the potential to move to a single dose in The US? I’d just be interested in your thoughts on the potential for a recommendation here and Merck’s ability to potentially adjust price in such an outcome. My follow-up was just on the manufacturing and kind of longer-term tariff. Mitigation efforts. Should we think about those efforts mostly focused on new products and pipeline or is there also an ability to address legacy products such as Keytruda with those longer-term efforts? Thank you.

Dr. Dean Li: Yeah, Chris. Thanks for the question. Let me address the Gardasil reduced dosing, and I think you’re specifically referring to ACIP and potential deliberations in relationship to reduced dosing. And I don’t wanna speculate what the ACIP may do, but I just want to emphasize that we are extremely confident in the safety and efficacy of the Gardasil nine and in the dosing regimen. And I would just emphasize, we have had clear firm, consistent, and recent guidance from the FDA on what would require for the licensure of a reduced dosing or a single dose. They are very clear on the high evidentiary standard. They point out to us that it must be efficacy against disease endpoints not just infections. You must have data in males and females.

Recognizing that HPV-related head and neck in males is actually greater here in The United States than cervical cancer. They emphasized to us high statistical bar, and they emphasize to us long-term durability of protection. The FDA is incredibly up to date and aware of the limitations of existing trials, and none meet the criteria for them to have a label change. So there appears to be a disparity between the stringent clinical requirements outlined by the FDA and some of the proposals that are in front of the ACIP. So what we are hopeful is that there will be a robust discussion and interrogation in a public setting in relationship to the clear disparity in the evidentiary standard set by us, set by the FDA to us, and the options that the ACIP is considering.

Caroline, did you wanna answer the other question?

Caroline Litchfield: Yes. So in terms of should the ACIP look towards any different type of dosing regimen, we stand firmly behind the value that Gardasil brings in preventing certain HPV-related cancers we will be looking to ensure that that cost-effectiveness is understood as we appropriately price the vaccine. Did you want to touch then on the second question, Rob? Which is the manufacturing and the longer term? Sorry about that.

Rob Davis: Yeah. I was enjoying your answer so much. Forgot the other question. Sorry about that. Chris, to your question about the manufacturing, it’s really both. So, clearly, we are very focused on new products, some of which we already have in The United States. Others, we’re gonna be moving to bring them to The United States. But we also were very focused on Keytruda. As you probably can surmise, our biggest exposure is Keytruda. In the near term, but I feel very good that as we sit here today with as I mentioned, the fact that we have, basically on-hand inventory in The United States to protect us through all of 2025. Then we’ve taken steps to be prepared both from a drug substance and a drug product as we move into 2026 and 2027 we’re as well-positioned as you could be through both the short-term actions on inventory as well as securing additional manufacturing in The United States.

Both the contract manufacturers, and then we are already underway to go to our own internal manufacturing. So we’re as well-positioned on KEYTRUDA as you can be. Obviously, we have to wait and see what the tariffs are, so I don’t wanna speak to the specific implications because it depends on the form they take. But I think we’re positioned on both Keytruda and the new products.

Peter Dannenbaum: Thank you, Chris. Next question, please.

James Shin: Next question is from James Shin from Deutsche Bank. Go ahead. Your line is open.

James Shin: Good morning. Thank you for the question. One for Rob. Rob, you’ve already disclosed a healthy amount of US investments. But is there a need for more or room for more US CapEx? And is it pending US tax reform? And then one for Dean. Has the recent PD one VEGF datasets made you and your team want to or maybe allocate more resources to l m two nine nine’s development? Thank you.

Rob Davis: Yeah, thanks for the question. So as we sit here today, as we mentioned between the $12 billion we’ve done plus the $9 billion plus we have underway. So we’re gonna be looking at, you know, north of $21 billion since 2018 as we look over the next few years. I actually think over time, you’re gonna see that grow. As we continue to because that’s based on the decision firm decisions we’ve already made. So that doesn’t include an expectation. That’s actually firm decisions. And as we think about bringing back manufacturing, I think you actually will see that number grow. The tax environment, obviously, we have to think holistically about all of this, but it is not going to affect how we think about investment. We think we can both do the necessary investments and manage our tax position quite effectively.

Dr. Dean Li: Yeah. In relationship to the PD one VEGF question, I think you’re referring to the I think it’s the Harmony two and six sort of readouts that’s come up. One of the things that’s actually very consistent that I think the field is looking for is whether any advancement in relationship to PFS over a single PD-one. Can be translated to an OS and whether something that’s in a China-only study can be done globally. Having said that, you know, we embrace the advancements in the field, and we think KEYTRUDA sets a high bar with 41 indications across 18 tumor types. As you know, we have our own p d one VEGF, and we will gate our decisions, in relationship to this as our data and other data, evolve. But as you point out, we believe strongly that we are the advantage owner given clinical expertise, extensive data generated, and that in some sense, we have both a Keytruda and a Leap playbook.

We would intend to move with speed and vigor. Most importantly or equally important is it should that p d one VEGF show that OS benefit, we also have an advantage of having unique portfolio agents that have clear potential for combinability. So we are looking at our own data and the data in the field as we make those decisions.

Rob Davis: And maybe I would just wanna add that, you know, should the bispecific be successful, you know, I think you can expect that the impact to us because of you know, this is likely to come frankly, probably post the LOE of Keytruda is pretty small. If you look across non-small cell lung cancer where potentially the competitor could be coming, by that time, we’ll only be mid-teens. It our business max. And remember, we are very hard working very, diligently to convert people to the earlier stage setting. And as we do so, they don’t have an indication there. So from that perspective, the risk to us is minimal. But I think what I really wanna emphasize the opportunity is significant. And I think that’s the point that Dean’s trying to make. I think this could be frankly, a really good thing for Merck long term.

Peter Dannenbaum: Great. Thanks, James. Next question, please.

Steve Scala: Next question from Steve Scala from TD Cowen. Go ahead. Your line is open.

Steve Scala: Thank you so much. Regarding GARDASIL growth slowdown globally, which seems to be a new disclosure, what new information emerged since Q1 when the company spoke to growth in each and every market. Is there still a line of sight to $11 billion which was repeated on the Q4 call? And is 02/2025 still the trough year? Thank you.

Caroline Litchfield: Thank you, Steve, for the question. First, the information that we’re providing with regards to the opportunities to grow Dartasil outside of China is not new. What we are highlighting, however, is a very effective execution by our colleagues in Japan of a catch-up cohort program that ends on the March 31 of this year. And as a result of that ending, we expect ourselves in just Japan to reflect the primary age cohort and therefore be reduced from quarter two onwards to what we have achieved over the prior quarters. As we look to Gardasil globally this year, we expect China to be a headwind. We had said previously with regards to China, we will assess do we or do we not ship further products this year at the midpoint of this year?

And we will do that assessment at the midpoint of this year. However, expect given the current dynamics in China, that is it is not so likely that we will ship further products in China, and that is actually an outcome that is incorporated into the midpoint of our guidance. All of that said, we do expect strong growth excluding China, strong double-digit we’ve achieved in the first quarter and we expect continued strong growth as we go through the remainder of the year. In terms of the longer-term guidance, we did withdraw the $11 billion target last quarter given the fact that China was an important part of the achievement of that $11 billion. Our company remains focused and on the ground in China to maximize the opportunity and maximize the launch in males while we’re working across the entirety of the world to protect many more lives from HPV-related cancers and drive growth for our business as we move forward.

Peter Dannenbaum: Great. Thanks, Steve. Next question, please.

Alex Hammond: Next question is from Alex Hammond from Wolfe Research. Go ahead. Your line is open.

Alex Hammond: Thanks for taking the question. So during the ACIP meeting, you spoke about the wording for the HPV recommendation from 11 to 12 years old eligible at nine to recommendation two nine to 12. That should be voted on at the June meeting. How important do you see this wording update to an impact to US sales? And from your doctor checks, you see the broader recommendation being material tailwind? Thank you.

Rob Davis: Yeah. Thanks for the question. As we look at what is the potential recommendation that could come in June, to your point, it appears that we could see them extend the recommendation to nine years old and up. Actually view that as a very important and positive development. Because of the fact that, one, as you look at adolescents who are being vaccinated in their early teens, to the extent that they will need multiple vaccinations it’s harder to get the fulfillment of the full vaccinations schedule. If you start at nine, we’re more apt to see people complete the schedule, which is a positive. And then in addition, at nine years old, you know, you’re at a time when there was not a lot of other vaccines happening. Vaccinations happening, and so there can be a focus on the Gardasil vaccination at a time when it’s, I think, easier for the family to prioritize and focus on it.

So we do see it as a positive. I wouldn’t view it as a big upside to The US. We’ve kind of you know, always viewed that this was an evolution that will be important. And in fact, while this will be an important recommendation, it’s already approved in that age cohort today. And in fact, you do see vaccinations happening. This recommendation, this reinforces it it’s coming from the ACIP. Great. Thanks, Alex. Next question, please.

Umer Raffat: Next question from Umer Raffat from Evercore. Go ahead. Your line is open.

Umer Raffat: Thanks for taking my question. I have a simple one perhaps, if I may. Rob, are you intending to keep the IP KEYTRUDA sub q here in US? Rather than Ireland as we head towards the potential approval? Thank you.

Rob Davis: Yeah. I actually, I don’t think we’ve ever disclosed where the IP is for sub q, and I don’t wanna, you know, get into a discussion of that. So I think I’ll would prefer not to speak to that just for proprietary reasons.

Peter Dannenbaum: Thanks, Umer. Next question, please.

Akash Tewari: Next question is from Akash Tewari from Jefferies.

Akash Tewari: So a few admittedly unfair questions on tariffs. One, is a 25% tariff a reasonable expectation? Or do you expect the headline number to be higher? What is your confidence that if they do get announced, they’ll at least be administered thoughtfully, whether it’s gradual implementation or expedited regulatory process. To move manufacturing to The US quickly, then finally, let’s say they end up being 25%. Could the impact to Merck with reasonable mitigation efforts be in the kind of single-digit range on earnings? On a percent basis? Thanks so much.

Rob Davis: Yeah. No. I appreciate the question. You know, I don’t wanna speculate on what the tariffs could be because we need to see what the language is from the administration. I think the important point is, as I previously stated, we have taken the steps both in terms of inventory management for the short term as well as starting to reposition manufacturing for the medium and long term that I think we are well-positioned under most scenarios that they could come through. But the specifics you’re looking for I don’t wanna speculate because we need to see what it is.

Peter Dannenbaum: Thanks, Akash. Next question, please.

Mohit Bansal: Next question is from Mohit Bansal from Wells Fargo. Go ahead. Your line is open.

Mohit Bansal: Hey, thank you very much for taking my questions. I have a question regarding the BD strategy. What we have seen lately is that you have acquired a bunch of assets from China. I mean, I mean, like, I completely understand the cost-effectiveness of them, but at the same time, it doesn’t seem like they are innovative area. Right? And all I did I think you are the first mover here. The top two, give for an healthy little a and even the Jet PD one. So it like, why doesn’t it feel like more like company like Merck is chasing the front runners here versus trying to be something you know? Do something innovative. We’d love to understand the thought process there. Thank you.

Dr. Dean Li: Yeah. I’ll take that question first. So first of all, I would remind us that I would sit there, and I would consider the Ocellarion purchase and winravir as bring a front-leading molecule would also sit there and consider that the move to t o 1 A Into Lasoka Park would be that as well. And I would reemphasize my excitement of our acquisition of iBio in relationship to wet AMD and diabetic macular edema. I should also emphasize that when you talk about certain compounds, let’s say, an LP little a or a GLP, would remind you also that we believe that we have we have an ambition to have the first and best oral PCSK nine. It will be first to market. We think it’ll be the most effective. We’re very confident in the cardiovascular outcomes.

But we’re also very confident in its ability to combine with certain agents. So when you look at some of the BD, I might not look at it as in isolation of the rest of the of the pipeline. I think that there are certain combinations that would be incredibly innovative that would require a combination but some of the innovation of the base of that innovation comes from comes from our company, and it’s a coordinated one pipeline, external, internal pipeline fusing into a final prod. Rob, did you wanna add anything?

Rob Davis: Yeah. Maybe just to, you know, reinforce, I think, couple points. We’ve been, I think, very balanced. Dean gave some great examples of where we are we are first in class and, frankly, best in class. We’re also looking at other strategies where we might not be first, but we still think we can be best in class. So I think you have to look at the total of the portfolio and not just the most recent three deals we’ve done, And I actually think you’ll see us continue to do a range of opportunities which cover the full spectrum. Because as we look at it, it’s about how do we position ourselves for growth. And in some cases, in some of these therapeutic areas, we’ve think there’s still unmet need. I mean, Dean highlighted a little bit, but obesity, there’s an opportunity for a next wave.

Depending on what comes with the p d one VEGF, that could be a next wave where frankly, when you combine it with other agents we have, we could lead as well. So don’t think it’s a fair characterization, and I would urge you to think more in terms of the total portfolio.

Peter Dannenbaum: Great. Thank you very much, Mohit. I think that puts us past the hour. So very much appreciate your time and attention this morning. And if you have any additional questions, please reach out to IR. Thank you all very much.

Operator: That concludes today’s conference. Thank you for participating. You may disconnect at this time.